Download PDF
Osteologie 2020; 29(01): 7-12
DOI: 10.1055/a-1076-1523
Originalarbeit

Knochen und Diabetes mellitus

Bone and Diabetes mellitus
Stephan H. Scharla
1   Praxis Innere Medizin, Endokrinologie & Diabetologie,, Bad Reichenhall, Germany
2   Medizinische Fakultät, Ludwig-Maximilians-Universität,, München, Germany
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Zusammenfassung

Diabetes mellitus ist mit einem erhöhten Risiko für Osteoporose und Frakturen assoziiert. Patienten mit Diabetes mellitus Typ 1 sind stärker betroffen, mit einem relativen Risiko für Hüftfrakturen von 2,5 bis 12. Das Risiko für Wirbelfrakturen ist bis 2-fach erhöht. Bei Patienten mit Diabetes mellitus Typ 2 ist das Frakturrisiko nicht so deutlich erhöht und mit der Zeitdauer der Diabetes-Erkrankung, dem Vorliegen von vaskulären Schäden, einer Neuropathie und mit einer Insulintherapie assoziiert. Ursachen für das gesteigerte Frakturrisiko sind toxische Effekte von hohen Glukosekonzentration auf Osteoblasten, die Glykierung von Knochenmatrixproteinen mit Veränderung der Kollagenstruktur, hormonelle Veränderungen und eine Störung der Knochenarchitektur. Das Frakturrisiko kann auch schon ohne deutliche Knochendichte-Minderung bereits erhöht sein. Die therapeutische Interventionsschwelle bei der Knochendichtemessung sollte deshalb in Richtung höhere Werte angepasst werden. Der Knochen als endokrines Organ moduliert aber auch den Zuckerstoffwechsel. Das aus dem Knochen freigesetzte untercarboxylierte Osteocalcin stimuliert die Insulinsekretion im Pankreas, verbessert die Insulinsensitivität und ist mit dem Risiko für die Manifestation des Diabetes mellitus assoziiert.

Abstract

Diabetes mellitus is associated with an increased risk for osteoporosis and fractures. Patients with diabetes mellitus type 1 are more severely affected (relative risk for hip fracture reaching from 2.5 to 12). The relative risk for vertebral fractures is doubled. In contrast, patients with diabetes mellitus 2 exhibit only a moderately increased fracture risk, which is associated with duration of diabetic disease, vascular disease, neuropathy, and insulin treatment. The causes for the increased fracture risk are toxic effects of high glucose concentrations on osteoblasts, the glycation of bone matrix proteins leading to changes in collagen structure, endocrine alterations, and changes in bone architecture. The fracture risk may be increased, even without significant loss of measured bone mineral density (BMD). Therefore, the therapeutic intervention threshold of BMD measurements has to be increased. Bone tissue is an endocrine organ and modulates sugar metabolism. Undercarboxylated osteocalcin released from bone stimulates insulin secretion in the pancreatic gland, improves insulin sensitivity and modulates the risk of diabetes manifestation.

Schlüsselwörter

Diabetes mellitus - Osteoporose - Frakturrisiko

Key words

Diabetes mellitus - osteoporosis - fracture risk


Publication History

Received: 05 December 2019

Accepted: 12 December 2019

Article published online:
25 February 2020

© Georg Thieme Verlag KG
Stuttgart · New York

 

  • Literatur

  • 1 Dachverband deutschsprachiger osteologischer Fachgesellschaften (DVO). S3–Leitlinie Osteoporose. www.dv-osteologie.org
    Google Scholar
  • 2 Neumann TK. Umbaumarker und diabetes. Osteologie 2014; 23: 91-96
    Article in Thieme ConnectGoogle Scholar
  • 3 Janghorbani M, Van Dam RM, Willet WC. et al. Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture. Am J Epidemiol 2007; 166: 495-505
    CrossrefPubMedGoogle Scholar
  • 4 Hothersall EJ, Livingstone SJ, Looker HC. et al. Contemporary risk of hip fracture in type 1 and type 2 diabetes: a national registry study from Scotland. J Bone Miner Res 2014; 29: 1054-1060
    CrossrefPubMedGoogle Scholar
  • 5 Vestergaard P, Rejnmark L, Mosekilde L. Relative fracture risk in patients with diabetes mellitus, and the impact of insulin and oral antidiabetic medication on relative fracture risk. Diabetologia 2005; 48: 1292-1299
    CrossrefPubMedGoogle Scholar
  • 6 Zhukouskaya VV, Eller-Vainicher C, Vadzianava VV. et al. Prevalence of morphometric vertebral fractures in patients with type 1 diabetes. Diabetes Care 2013; 36: 1635-1640
    CrossrefPubMedGoogle Scholar
  • 7 Wyers CE, Vranken L, van der Velde RY. et al. Cardiovascular Risk Factor Analysis in Patients with a Recent Clinical Fracture at the Fracture Liaison Service. Biomed Res Int. 2014; 2014: 710945. DOI: 10.1155 / 2014 / 710945. Epub 27 Aug 2014
    CrossrefPubMedGoogle Scholar
  • 8 Wallander M, Axelsson KF, Nilsson AG. et al. Type 2 diabetes and risk of hip fractures and non-skeletal fall injuries in the elderly: a study from the fractures and fall injuries in the elderly cohort (FRAILCO). J Bone Miner Res 2017; 32: 449-460
    CrossrefPubMedGoogle Scholar
  • 9 Napoli N, Schwartz AV, Schafer A. for the Osteoporotic Fractures in Men (MrOS) Study Research Group. et al. Vertebral fracture risk in diabetic elderly men: the MrOS study. J Bone Mineral Res 2018; 33: 63-69 .
    CrossrefPubMedGoogle Scholar
  • 10 Jia P, Bao L, Chen H. et al. Risk of low-energy fracture in type 2 diabetes patients: a meta-analysis of observational studies. Osteoporos Int 2017; 28: 3113-3121
    CrossrefPubMedGoogle Scholar
  • 11 Kiyohara N, Yamamoto M, Sugimoto T. Discordance between prevalent vertebral fracture and vertebral strength estimated by the finite element method based on quantitative computed tomography in patients with type 2 diabetes mellitus. PLoS One 2015; 10 (12) : e0144496. DOI: 10.1371 / journal.pone.0144496. eCollection 2015.
    CrossrefPubMedGoogle Scholar
  • 12 Jung JK, Kim HJ, Lee HK. et al. Fracture incidence and risk of osteoporosis in female type 2 diabetic patients in Korea. Diabetes Metab J 2012; 36: 144
    CrossrefPubMedGoogle Scholar
  • 13 Forsen L, Meyer HE, Midthjell K. et al. Diabetes mellitus and the incidence of hip fracture: results from the nord-trondelag health survey. Diabetologia 1999; 42: 920
    CrossrefPubMedGoogle Scholar
  • 14 Napoli N, Strotmeyer ES, Ensrud KE. et al. Fracture risk in diabetic elderly men: the MrOS study. Diabetologia 2014; 57: 2057-2065
    CrossrefPubMedGoogle Scholar
  • 15 Majumdar SR, Leslie WD, Lix LM. et al. Longer duration of diabetes strongly impacts fracture risk assessment: the manitoba BMD cohort. J Clin Endocrinol Metab 2016; 101: 4489-4496
    CrossrefPubMedGoogle Scholar
  • 16 Wang H, Ying B, Xing Q. et al. Diabetes mellitus and the risk of fractures at specific sites: a meta-analysis. BMJ Open 2019; 9: e023067. DOI:10.1136/bmjopen-2018-024067
    Google Scholar
  • 17 Botolin S, McCabe LR. Chronic hyperglycemia modulates osteoblast gene expression through osmotic and non-osmotic pathways. J Cell Biochem 2006; 99: 411-424
    CrossrefPubMedGoogle Scholar
  • 18 Vashishth D, Gibson GJ, Khoury JI. et al. Influence of nonenzymatic glycation on biomechanical properties of cortical bone. Bone 2001; 28: 195-201
    CrossrefPubMedGoogle Scholar
  • 19 Schwartz A, Garnero P. Hi Pentosidine and increased fracture risk in older adults with type 2 diabetes. J Clin Endocrinol Metab 2009 94: 2380-2386
    Google Scholar
  • 20 Kindler JM, Laing EM, Liu W. et al. Pentosidine is associated with cortical bone geometry and insulin resistnce in otherwise healthy children. J Bone Miner Res 2019; 34: 1446-1450
    CrossrefPubMedGoogle Scholar
  • 21 Farr JN, Drake MT, Amin S. et al. In vivo assessment of bone quality in postmenopausal women with type 2 diabetes. J Bone Miner Res 2014; 29: 787-795
    CrossrefPubMedGoogle Scholar
  • 22 Hunt HB, Torres AM, Palomino PM. et al. Altered tissue composition, microarchitecture, and mechanical performance in cancellous bone from men with type 2 diabetes mellitus. J Bone Miner Res 2019; 34: 1191-1206
    CrossrefPubMedGoogle Scholar
  • 23 Li C-I, Liu C-S, Lin W-Y. et al. Glycated hemoglobin level and risk of hip fracture in older people with type 2 diabetes: a competing risk analysis of taiwan diabetes cohort study. J Bone Miner Res 2015; 30: 1338-1346
    CrossrefPubMedGoogle Scholar
  • 24 Kalaitzoglou E, Popescu I, Bunn RC. et al. Effects of type 1 diabetes osteoblasts, osteocytes and osteoclasts. Curr Osteoporos Rep 2016; 14: 310-319
    CrossrefPubMedGoogle Scholar
  • 25 Henrikson DB, Alexandersen P, Hartmann B. et al. Four-month treatment with GLP-2 significantly increases hip BMD: a randomized, placebo-controlled, dose ranging study in postmenopausal women with low BMD. Bone 2009; 45: 833-842
    CrossrefPubMedGoogle Scholar
  • 26 Nissen A, Marstrand S, Skov-Jeppesen K. et al. A pilot study showing acute inhibitory effect of GLP-1 on the bone resorption marker CTX in humans. JBMR Plus. 2019; 3: e10209. DOI: 10.1002 / jbm4.10209.
    CrossrefPubMed
  • 27 Scharla S. Osteoporose bei Typ -1- und Typ-2-Diabetes mellitus. Arthritis + rheuma 2017; 37: 395-400
    Google Scholar
  • 28 Hough FS, Pierroz DD, Cooper C. the IOF CSA Bone and Diabetes Working Group. et al. Eur J Endocrinol 2016; 174: R127-R138
    CrossrefPubMed
  • 29 Scharla SH, Lempert UG. 25-hydroxyvitamin D and vitamin D-binding protein (DBP) in patients with obesity and diabetes mellitus type 2. DGE -Tagung 2016, Poster, URN:urn.nbn:de: 101: 1-201604282025
    Google Scholar
  • 30 Goulding A, Taylor RW. Plasma leptin values in relation to bone mass and density and to dynamic biochemical markers of bone resorption and formation in postmenopausal women. Calcif Tissue Int 1998; 63: 456-458
    CrossrefPubMedGoogle Scholar
  • 31 Lacombe J, Cairns BJ, Green J. for the Million Women Study collaborators. et al. The effects of age, adiposity, and physical activity on the risk of seven site-specific fractures in postmenopausal women. J Bone Miner Res. 2016; 31: 1559-1568
    CrossrefPubMedGoogle Scholar
  • 32 Ishii S, Cauley JA, Greendale GA. et al. Pleiotropic effects of obesity on fracture risk: the study of women’s health across the nation. J Bone Miner Res 2014; 29: 2561-2570
    CrossrefPubMedGoogle Scholar
  • 33 Johansson H, Kanis JA, Oden A. et al. A Meta-Analysis of the association of fracture risk and body mass index in women. J Bone Miner Res 2014; 29: 223-233
    CrossrefPubMedGoogle Scholar
  • 34 Majumdar SR, Josse RG, Lin M. et al. Does Sitagliptin affect the rate of osteoporotic fractures in type 2 diabetes? Population-based cohort study. J Clin Endocrinol Metab 2016; 101: 1963-1969
    CrossrefPubMedGoogle Scholar
  • 35 Chandran M. Diabetes Drug Effects on the Skeleton. Calcif Tissue Int 2017; 100: 133-149
    CrossrefPubMedGoogle Scholar
  • 36 Monami M, Antenore A, Dicembrini I. et al. Dipeptidyl peptidase-4 inhibitors and bone fractures. A meta-analysis of randomized clinical trials. Diab Care 2011; 34: 2474-2476
    CrossrefPubMedGoogle Scholar
  • 37 Dombrowski S, Kostev K, Jacob L. Use of dipeptidyl peptidase-4 inhibitors and risk of bone fracture in patients with type 2 diabetes in Germany – A retrospective analysis of real-world data. Osteoporos Int 2017; 28: 2421-2428
    CrossrefPubMedGoogle Scholar
  • 38 Kohan DE, Fioretto P, Tang W. et al. Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int 2014; 85: 962-971
    CrossrefPubMedGoogle Scholar
  • 39 Lee NK, Sowa H, Hinoi E. et al. Endocrine regulation of energy metabolism by the skeleton. Cell 2007; 130: 456-469
    CrossrefPubMedGoogle Scholar
  • 40 Ferron M, Wie J, Yoshizawa T. et al. Insulin signaling in osteoblasts bone remodeling and energy metabolism. Cell 2010; 142: 296-308
    CrossrefPubMedGoogle Scholar
  • 41 Pittas AG, Harris SS, Eliades M. et al. Association between serum osteocalcin and markers of metabolic phenotype. J Clin Endocrinol Metab 2009; 94: 827-832
    CrossrefPubMedGoogle Scholar
  • 42 Bullo M, Moreno-Navarette JM, Fernandez-Real JM. et al. Total and undercarboxylated osteocalcin predict changes in insulin sensitivity and β cell function in elderly men at high cardiovascular risk. Am J Clin Nutr 2012; 95: 249-255
    CrossrefPubMedGoogle Scholar
  • 43 Levinger I, Zebaze R, Jerums G. et al. The effect of acute exercise on undercarboxylated osteocalcin in obese men. Osteoporos Int 2011; 22: 1621-1626
    CrossrefPubMedGoogle Scholar
  • 44 Levinger I, Jerums G, Stepto NK. et al. The effect of acute exercise on undercarboxylated osteocalcin and insulin sensitivity in obese men. J Bone Mineral Res 2014; 29: 2571-2576
    CrossrefPubMedGoogle Scholar
  • 45 Lin X, Parker L, McLennan E. et al. Undercarboxylated osteocalcin improves insulin-stimulated glucose uptake in muscles of corticosterone-treated mice. J Bone Miner Res 2019; 34: 1517-1530
    CrossrefPubMedGoogle Scholar
  • 46 Yeap BB, Alfonso H, Chubb SAP. et al. Higher serum undercarboxylated osteocalcin and other bone turnover markers are associated with reduced diabetes risk and lower estradiol concentrations in older men. J Clin Endocrinol Metab 2015; 100: 63-71
    CrossrefPubMedGoogle Scholar
  • 47 Lin X, Brennan-Speranza TC, Levinger I. et al. Undercarboxylated osteocalcin: Experimental and human evidence for a role in glucose homeostasis and muscle regulation of insulin sensitivity. Nutrients 2018; 847 . DOI: 10.3390/nu10070847.
    CrossrefPubMedGoogle Scholar
  • 48 Ma H, Ma JX, Xue P. et al. Osteoblast proliferation is enhanced upon the insulin receptor substrate 1 overexpression via PI3K signaling leading to down-regulation of NFkB and BAX Pathway. Exp Clin Endocrinol Diabetes 2015; 123: 126-131
    Article in Thieme ConnectPubMedGoogle Scholar
  • 49 Turner RT, Kalra SP, Wong CP. et al. Peripheral Leptin Regulates Bone Formation. J Bone Mineral Res 2013; 28: 22-34
    CrossrefPubMedGoogle Scholar
  • 50 Razny U, Fedak D, Kiec-Wilk B. et al. Carboxylated and undercarboxylated osteocalcin in metabolic complications of human obesity and prediabetes. Diabetes Metab Res Rev 2017; 33: e2862
    CrossrefPubMedGoogle Scholar
  • 51 Rashdan NA, Sim AM, Cui L. et al. Osteocalcin regulates arterial calcification via altered Wnt signaling and glucose metabolism. J Bone Miner Res 2019; online vor Druck: DOI: https://doi.org/10.1002/jbmr.3888.
    CrossrefPubMedGoogle Scholar
  • 52 Hadjidakis D, Androulakis II, Mylonakis AM. et al. Diabetes in postmenopause: different influence on bone mass according to age and disease duration. Exp Clin Endocrinol Diabetes 2009; 117: 199
    Article in Thieme ConnectPubMedGoogle Scholar
  • 53 Scharla SH. Bei Diabetikern an eine Osteoporose denken. MMW Fortschr Med 2018; 160 (21–22): 65-69
    PubMedGoogle Scholar